A user is using oral finasteride, oral dutasteride, and drinking topical minoxidil for hair loss, despite health warnings. Switching from finasteride to dutasteride did not improve hair density.
Finasteride and minoxidil are commonly recommended by hair transplant clinics, including those in Turkey, despite some negative perceptions and concerns about side effects. The conversation highlights differing opinions on the effectiveness and safety of these treatments, with some users expressing skepticism about side effects and others emphasizing the importance of these medications for successful hair transplants.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.
The user has been using finasteride for 4 years and minoxidil for 1 year, with a recent break from minoxidil due to shedding concerns. They resumed minoxidil and started dutasteride 3 times a week, but are experiencing increased hair shedding.
People are sharing their experiences with different dosages of dutasteride and finasteride for hair loss. Many report shedding initially but some see improvements over time, with some also using minoxidil.
The conversation discusses the pros and cons of using propylene glycol versus ethyl alcohol in topical solutions for finasteride and minoxidil. It questions why propylene glycol is commonly used and whether ethyl alcohol might be a better option.
Monthly microneedling combined with low-dose topical dutasteride shows promising results for hair density and thickness with minimal side effects, especially in the frontal area. Despite its effectiveness, it is not widely discussed or used due to availability and cost concerns.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
A person with hair loss since COVID-19 is considering treatments like finasteride and minoxidil but is hesitant due to potential side effects. Suggestions include visiting a dermatologist, using a ketoconazole shampoo, and considering that post-COVID hair loss might be an autoimmune response.
Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.
A 17-year-old is experiencing diffuse thinning, dandruff, body hair shedding, and other symptoms, possibly linked to seborrheic dermatitis or telogen effluvium. They are using ketoconazole shampoo and considering blood tests to check for thyroid issues or deficiencies.
The user experienced red pimples and a rash from using topical minoxidil, possibly due to propylene glycol. Suggestions included seeing a dermatologist, switching to foam without propylene glycol, using Nizoral, and adjusting application timing.
The conversation discusses hair loss treatments, focusing on insulin resistance, microneedling with topical melatonin, and stress reduction. Users express skepticism about the advice, preferring proven treatments like minoxidil and finasteride, while some mention alternative methods like dermal incisions and verteporfin for reducing fibrosis.
Oral minoxidil combined with finasteride can improve hair density, but long-term safety is uncertain due to potential side effects like heart and kidney issues. Users report mixed experiences, with some experiencing side effects and others finding it effective for hair maintenance.
The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.
The user reported minimal results for the first 7-8 months using finasteride every other day and minoxidil once a day, but recently noticed hairline improvement and increased density. They also started microneedling once a week.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.
The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
The dermatologist prescribed topical finasteride and minoxidil, but only finasteride is available in pill form. The user plans a telehealth visit to discuss options.
A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.